公开(公告)号：US20240208954A1

公开(公告)日：2024-06-27

申请号：US18013696

申请日：2021-06-29

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Hong LIU ,  Jiang WANG ,  Cen XIE ,  Yameng LIU ,  Shulei HU ,  Cuina LI ,  Feng GAO ,  Kanglong WANG ,  Yong WANG ,  Xianchun ZHONG ,  Yuqiang SHI ,  Hualiang JIANG ,  Kaixian CHEN

IPC分类号： C07D413/10 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/675 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  C07D271/06 ,  C07D413/14 ,  C07F9/6558

CPC分类号： C07D413/10 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/675 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  C07D271/06 ,  C07D413/14 ,  C07F9/65583

摘要： The present invention relates to the fields of pharmaceutical chemistry and pharmacotherapeutics, and in particular to a compound as represented by general formula I, a racemate, an R-isomer, an S-isomer and a pharmaceutically acceptable salt thereof and a mixture of same, a preparation method therefor, a pharmaceutical composition containing the compound and the use thereof as an SIP receptor agonist. The oxadiazole compound involved in the present invention can be used for treating SIP receptor agonist related diseases.